- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome
Patients with Down syndrome are at an increased risk for developing leukemia, but how much of an increased risk depends on age, explained Irene Roberts, MD, professor of pediatric hematology, MRC molecular hematology unit and pediatrics, MRC Weatherall Institute of Molecular Medicine.
Patients with Down syndrome are at an increased risk for developing leukemia, but how much of an increased risk depends on age, explained Irene Roberts, MD, professor of pediatric hematology, MRC molecular hematology unit and pediatrics, MRC Weatherall Institute of Molecular Medicine.
Transcript
How at risk are patients with Down syndrome for developing leukemia compared with the general population?
That very much depends on the age. So, for example, in a lifetime, say up to age 60, there’s about a 12-fold increased risk of acute myeloid leukemia compared to individuals without Down syndrome and a 13-fold increase of acute lymphoblastic leukemia. But if you’re a young child, the statistics are a lot different. So, the risk of a myeloid leukemia in children under 4, for example, climbs to 114-fold compared to other young children who don’t have Down syndrome.
What’s the reason behind this risk?
That’s a very good question, and we don’t fully know the answer, and a lot of people are researching on that. The assumption is that it has something to do with the extra chromosome in the blood cells. So, having an extra chromosome, 21, in some way, affects the behavior of the blood cell, which makes it more likely to transform. But which genes do it, we still don’t know.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
